VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol

Amanda J. Hooper; Xuan L. Tang; John R. Burnett

doi:10.1080/13543784.2024.2369747

VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol

Research output: Contribution to journal › Editorial › peer-review

Original language	English
Pages (from-to)	753-756
Number of pages	4
Journal	Expert Opinion on Investigational Drugs
Volume	33
Issue number	8
DOIs	https://doi.org/10.1080/13543784.2024.2369747
Publication status	Published - 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1080/13543784.2024.2369747

Cite this

@article{5408ac5906a64e4b9ab42c729dbb51f8,

title = "VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol",

keywords = "Base editing, CRISPR, LDL, LDL-cholesterol, PCSK9, PCSK9 inhibitor, VERVE-101, VERVE-102",

author = "Hooper, \{Amanda J.\} and Tang, \{Xuan L.\} and Burnett, \{John R.\}",

year = "2024",

doi = "10.1080/13543784.2024.2369747",

language = "English",

volume = "33",

pages = "753--756",

journal = "Expert Opinion on Investigational Drugs",

issn = "1354-3784",

publisher = "Taylor \& Francis",

number = "8",

}

TY - JOUR

T1 - VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol

AU - Hooper, Amanda J.

AU - Tang, Xuan L.

AU - Burnett, John R.

PY - 2024

Y1 - 2024

KW - Base editing

KW - CRISPR

KW - LDL

KW - LDL-cholesterol

KW - PCSK9

KW - PCSK9 inhibitor

KW - VERVE-101

KW - VERVE-102

UR - https://www.scopus.com/pages/publications/85196614768

U2 - 10.1080/13543784.2024.2369747

DO - 10.1080/13543784.2024.2369747

M3 - Editorial

C2 - 38878270

AN - SCOPUS:85196614768

SN - 1354-3784

VL - 33

SP - 753

EP - 756

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

IS - 8

ER -

VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol

UN SDGs

Access to Document

Other files and links

Cite this